# Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine

> **NCT02114060** · PHASE2 · COMPLETED · sponsor: **Genocea Biosciences, Inc.** · enrollment: 310 (actual)

## Conditions studied

- Genital Herpes Simplex Type 2

## Interventions

- **BIOLOGICAL:** GEN-003 Vaccine (30μg of each antigen)
- **BIOLOGICAL:** GEN-003 Vaccine (60μg of each antigen)
- **BIOLOGICAL:** Matrix-M2 Adjuvant (25μg)
- **BIOLOGICAL:** Matrix-M2 Adjuvant (50μg)
- **BIOLOGICAL:** Matrix-M2 Adjuvant (75μg)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02114060
- **Lead sponsor:** Genocea Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2017-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02114060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02114060, "Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02114060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*